205 related articles for article (PubMed ID: 26458437)
1. [Current treatment strategies for myelodysplastic syndromes].
Suzuki T
Rinsho Ketsueki; 2015 Oct; 56(10):1985-95. PubMed ID: 26458437
[TBL] [Abstract][Full Text] [Related]
2. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
3. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
4. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
[TBL] [Abstract][Full Text] [Related]
5. [Hematologic response predictor factors in adults with myelodysplastic syndromes (SMD) treated with cyclosporin A (CSA)].
Zamora-Pérez E; López-Karpovitch X
Gac Med Mex; 2015; 151(3):345-53. PubMed ID: 26089271
[TBL] [Abstract][Full Text] [Related]
6. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
8. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
9. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K; Stankov S; Katanic J
Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
[TBL] [Abstract][Full Text] [Related]
10. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.
Gore SD; Hermes-DeSantis ER
Cancer Control; 2009 Oct; 16 Suppl():2-10. PubMed ID: 20010512
[TBL] [Abstract][Full Text] [Related]
11. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
12. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes.
Hofmann WK; Lübbert M; Hoelzer D; Phillip Koeffler H
Hematol J; 2004; 5(1):1-8. PubMed ID: 14745424
[TBL] [Abstract][Full Text] [Related]
14. [Identification of myelodysplastic syndromes patients].
Santini V
Recenti Prog Med; 2014 Mar; 105(3):127-31. PubMed ID: 24675456
[TBL] [Abstract][Full Text] [Related]
15. Update on the therapy for myelodysplastic syndrome.
Kasner MT; Luger SM
Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
[TBL] [Abstract][Full Text] [Related]
16. Established and novel agents for myelodysplastic syndromes.
Sekeres MA; Gerds AT
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):82-9. PubMed ID: 25696839
[TBL] [Abstract][Full Text] [Related]
17. Clinical roundtable monograph. Overall survival and maintenance of MDS patients.
Silverman LR
Clin Adv Hematol Oncol; 2009 Jul; 7(7):S3-5. PubMed ID: 19708287
[TBL] [Abstract][Full Text] [Related]
18. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
[TBL] [Abstract][Full Text] [Related]
19. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
20. [Myelodysplastic syndromes].
Solary E; Fontenay M
Rev Prat; 2010 Dec; 60(10):1408-9, 1412. PubMed ID: 21425540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]